Clinical Trial Portfolio

The portfolio includes a range of projects from first in human drug trials through to large Phase III clinical studies. Studies assess interventions including radiotherapy, drug combinations and novel imaging techniques.

• Early phase.
• Radiotherapy and Imaging.
• Data Rich Trials.

Prospective Clinical Trials

• CEDAR: A Phase 1 trial of the safety, tolerability and biological effects of intravenous Enadenotucirev, a novel oncolytic virus, in combination with chemoradiotherapy in locally advanced rectal cancer

Active Clinical Trials

• CHARIOT: A Phase I dose escalation safety study combining the ATR inhibitor M6620 with chemoradiotherapy in oesophageal cancer & other solid cancers using time to event continual reassessment method
• CYTOFLOC: Evaluation of a Non‐Endoscopic Immunocytological Device (Cytosponge™) for post chemo‐radiotherapy surveillance in patients with oesophageal cancer – a feasibility study
• IMAGO: A single arm exploratory study examining the feasibility of imaging glioblastoma pH using CEST MRI
• IP-GLIO: A Phase II, Open Label, Randomised Study of Ipilimumab with Temozolomide versus Temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma
• LUD2015-005: Phase 1/2 Study of anti-PD-L1 in Combination with Chemo(radio)therapy for Oesophageal Cancer
• MErCuRIC 1: A Sequential Phase I study of MEK 1/2 inhibitors PD-0325901 or Binimetinib combined with cMET inhibitor PF-02341066 in Patients with RAS Mutant and RAS Wild Type (with aberrant c-MET) Colorectal Cancer
• NEOPANC-01: A phase 0, pre-operative, window-of-opportunity study to assess gene expression in patients with resectable pancreatic cancer 
• NuTIDE:301: A two-part, Phase 1 open-label dose escalation and expansion study to assess safety, pharmacokinetics and clinical activity of NUC-3373, a nucleotide analogue, in participants with advanced solid tumours. 
• OCTOVA: Randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with BRCA mutated platinum-resistant ovarian cancer
• PemBla: A parallel group, open-label, multi-centre, randomised, phase I/II marker-lesion study of intravesical or intravenous pembrolizumab. 
• SCALOP-2: A multi-centre randomised study of induction chemotherapy followed by capecitabine (+/- nelfinavir) with high or standard dose radiotherapy for locally advanced non-metastatic pancreatic cancer

In Follow-up

• ATOM: Pre-operative window of opportunity study of the effects of atovaquone on hypoxia in non-small cell lung carcinoma
• CAMELLIA: A Phase I dose escalation trial of the Humanized Anti-CD47 Monoclonal Antibody Hu5F9-G4 in Haematological Malignancies
• DOC-MEK: A double blind randomised phase 2 trial of docetaxel with or without AZD6244 in wt BRAF advanced melanoma.  To determine the efficacy and tolerability of the combination of the selective MEK inhibitor AZD6244 with docetazel in patients with wild-type BRAF metastatic melanoma.
• SPARC: Stereotactic Body Radiotherapy (SBRT) pre-operatively for pancreatic cancer: A Phase I trial of pre-operative, margin intensive, stereotactic body radiation therapy for pancreatic cancer.
• WBRT: Whole Brain Radiotherapy following local treatment of intracranial metastases of melanoma – A randomised Phase III trial.  

Completed

• 6MP: A Phase II Clinical trial in patients with known BRCA Defective Tumours.
• ART: Anal squamous cell carcinoma: Investigation of functional imaging during Chemoradiotherapy (CRT)
• AspECT: A Phase III, randomised study of aspirin and esomeprazole chemoprevention in Barrett's metaplasia.
• BKM120: A CR-UK phase I study of BKM120 in patients with non-small cell lung cancer (NSCLC) receiving thoracic radiotherapy.
• CHOP-OR: Phase II single arm multi-centre NCRI feasibility study of CHOP combined with Ofatumumab in induction and maintenance for patients with newly diagnosed Richter’s syndrome. 
• COG: Randomised phase III trial of gefitinib 500mg once daily versus placebo in oesophageal cancer progressing after chemotherapy.
• DATACAP: Dose Adaptation of Capecitabine Using Mobile Phone Toxicity Monitoring: A Pilot Study of Optimal Dose Scheduling of Capecitabine for Patients with Metastatic Colorectal or Metastatic Breast Cancer.
• DEBIOC: A Phase I dose-escalating and safety study of AZD8931 in combination with Oxaliplatin and Capecitabine chemotherapy in patients with Oesophago-gastric adenocarcinoma
• EnROL: Conventional versus laparoscopic surgery for colorectal cancer within an enhanced programme.
• FOXFIRE: An open-label randomised phase III trial of 5-Fluorouracil, OXaliplatin and Folinic acid +/- Interventional Radio-Embolisation as first line treatment for patients with unresectable liver-only or liver-predominant metastatic colorectal cancer.
• FRONTIER: An open-labelled study to characterise Fluciclovine (¹⁸F) uptake measured by positron emission tomography in breast cancer
• LINES: Eurosarc Trial of Linsitinib in advanced Ewing Sarcoma
• MEMOS: 
• Mobile Phone Project: Using GPRS mobile phone technology for managing symptoms associated with chemotherapy for colon cancer
• OXO-PCR-01: A Single-Centre Prospective Phase 0 Translational Study for Predicting Response of High Grade Serous Ovarian Cancers to Paclitaxel Chemotherapy
• PACMEL: A randomised phase 2 study of paclitaxel with or without GSK1120212 or pazopanib in advanced wt BRAF melanoma
• QUASAR 2: A multicentre international study of capecitabine ± bevacizumab as adjuvant treatment of colorectal cancer.
• RADVAN: A randomised double blind phase 2 trial of whole brain radiotherapy with or without vandetanib in metastatic melanoma with brain metastases.
• RHYTHM-1: Modulation of Radiotherapy according to HYpoxia: exploiting changes in the Tumour Microenvironment to improve outcome in rectal cancer
• SCOT: Short Course Oncology Treatment - A study of adjuvant chemotherapy in colorectal cancer by the  CACTUS and OCTO groups.
• SONATINA: A Phase II Multi-Centre Randomised Controlled Study Of Nelfinavir Addition to Radiotherapy Treatment In Neo-Adjuvant Therapy for Rectal Cancer.
• TARDOX: A Proof of Concept Study to Investigate the Feasibility of Targeted Release of Doxorubicin from Lyso-thermosensitive Liposomal (LTSL) Doxorubicin (ThermoDox®) Using Focused Ultrasound in Patients with Primary or Secondary Liver Tumours.
• VICTOR: Post-treatment stage of a Phase III, randomised, double blind, placebo-controlled study of rofecoxib (VIOXX®) in colorectal cancer patients following potentially curative therapy.